As the incidence of COVID-19 cases continue to rise, we will need multiple approaches to effectively deal with this pandemic. Clinicians are evaluating Favipiravir for use in mild-to-moderate COVID-19 disease, which if administered early, may shorten time to recovery and keep the infection from progressing into severe disease.
We welcome to join a timely webinar to learn and discuss "Benefit of early intervention & role of Favipiravir in managing mild to moderate COVID-19 disease".
What will be covered:
- Early intervention benefits and role of Favipiravir (35min)
- Real world experience with Favipiravir (35min)
- Q & A (20min)
Our speakers are:
1. Dr. Mangesh Tiwasker, Consultant Physician & Diabetologist, Shilpa Medical Research Centre, Mumbai, Hon. G. Secretary: National API / ICP / PRF, who will share his experiences in "Early intervention benefits and role of Favipiravir".
2. Dr. Agam Vora, Chest Physician, Medical Director, Advanced Multi Specialty Hsp., Mumbai, Hon. G. Secretary of Academy of Advanced Medical Education, who will share "Real world evidence experience with Favipiravir".
We wish you a great learning experience and thank our sponsors Mylan Pharmaceuticals Pvt. Ltd. to make this program possible.
Please download and install Zoom app on your phone or desktop: https://zoom.us/